Eylea (generic name: aflibercept) is an injectable solution used to treat several eye conditions that affect vision, including neovascular age-related macular degeneration (wet AMD), impaired vision due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), impaired vision due to diabetic macular edema (DME), and impaired vision due to myopic choroidal neovascularisation (myopic CNV). Aflibercept belongs to a class of drugs called anti-angiogenics, specifically targeting proteins responsible for the growth of abnormal blood vessels in the retina, which can leak fluid and cause vision loss. It works by inhibiting Vascular Endothelial Growth Factor A (VEGF-A) and Placental Growth Factor (PlGF), both of which contribute to the abnormal formation of blood vessels in the eye. By blocking these proteins, Eylea helps to stop further vision deterioration and, in many cases, improve visual acuity. A doctor delivers the drug through an intravitreal injection directly into the eye, where it can reduce swelling, prevent fluid leakage, and stabilize vision loss. Eylea has been shown to stop the growth of new abnormal blood vessels in the eye, which often leak fluid or bleed. Eylea can help stabilize and, in many cases, reduce vision loss related to wet AMD, CRVO, BRVO, DME, and myopic CNV. Eylea is commonly prescribed to adults with conditions that affect the macula, a part of the retina crucial for sharp central vision. Its therapeutic effects can significantly benefit individuals with severe vision impairment related to the above conditions.

Dosage

Eylea requires regular injections, with the frequency determined by the treating ophthalmologist based on individual needs and responses to treatment. The exact dosing schedule may vary based on the progression of the disease and individual patient response. The typical dosing regimen for Eylea involves an initial series of monthly injections followed by less frequent maintenance doses, depending on the specific condition being treated. For example, patients with wet AMD may receive three initial injections, followed by one injection every two months. Cautions

Women of childbearing potential have to use effective contraception during treatment and for at least three additional months after the last injection of Eylea. If pregnancy occurs while undergoing treatment with Eylea, inform the prescribing doctor at once.

Eylea can cause some temporary visual disturbances. Do not drive or use machines as long as these disturbances last.

Storage

Eylea should be stored in the refrigerator at 2°-8°C (36-46°F). It must not be frozen and should be kept in its original packaging to protect it from light. Before administration, the solution should be inspected for discoloration or particulate matter. Eylea must be shipped to you in cold-chain storage, for which a charge is made.

Questions People Ask About Eylea

How often do you need Eylea injections?

The frequency of Eylea injections depends on the condition being treated. Typically, patients receive an initial series of monthly injections, followed by maintenance doses every two months. The ophthalmologist determines the specific schedule based on individual needs and treatment response.

Is Eylea painful?

Eylea injections can cause some discomfort, but most patients describe the pain as mild and short-lived. The eye is typically numbed before the injection to minimize discomfort. Any pain or irritation should resolve soon after the procedure, but if it persists, contact a healthcare provider.

What conditions does aflibercept treat?

Aflibercept treats conditions like wet age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema from retinal vein occlusion (RVO), and myopic choroidal neovascularization (myopic CNV), all of which can lead to vision loss if untreated.